◆ NeutralNVOLLY
Novo Nordisk Just Delivered Great News for Investors. Is a Comeback Finally Underway?
The Motley Fool·
Novo Nordisk reported strong Q3 2026 results driven by its oral weight-loss pill, which generated $810 million in revenue with over 3 million prescriptions. The company raised its full-year guidance and the stock jumped 6% post-earnings. With upcoming catalysts including international expansion of oral Wegovy, new product launches like CagriSema, and promising pipeline candidates, analysts suggest the company is staging a comeback after a difficult two-year period.
Read Full Article at The Motley Fool →